Artificial Intelligence (AI) is transforming clinical research. From improving protocol design to identifying eligible patients and monitoring data in real time, AI is speeding up every stage of the clinical trial process. For sponsors, Contract Research Organizations (CROs), and research sites, it offers the opportunity to increase efficiencies, shorten timelines, reduce costs and helps to personalize the patient experience.
But alongside AI’s benefits and ability to accelerate clinical trials, it also brings challenges. And there remains a key part of the clinical trial process that AI cannot yet command – empathetic engagement with patients. In an increasingly digital world, human connection, like the kind we employ through our Patient Support Center (link: /services/navigator), remains essential for trial participants and crucial for patient retention. We must embrace both approaches, and understand how each one complements the other for maximum impact.
AI in clinical trial design and planning
Smarter protocol development
AI can analyze historical trial data, published research, and real-world evidence to help identify optimal study designs. This includes refining inclusion and exclusion criteria, determining dosing regimens, and predicting recruitment challenges before a trial even begins. Smarter planning helps prevent protocol amendments later, keeping trials on track.
Predictive site and patient selection
By analyzing large datasets such as electronic health records and demographic information, AI can pinpoint the most appropriate sites for a particular study and which patient populations, and subpopulations, are best suited to participate. This data-driven insight means resources can be directed to where they’ll have the most impact.
AI in clinical trial patient recruitment
Faster and more accurate matching
Recruitment is typically one of the slowest parts of the clinical trial process; it is widely acknowledged that about 80% of clinical trials miss their enrollment deadlines, costing sponsors considerable sums of money and delaying patient access to new and innovative medicines [1,2]. AI tools have the potential to help us reverse this by rapidly scanning health records, lab results and unstructured medical notes to identify patients who meet the study criteria. Algorithms also help remove manual bias by ensuring that screening decisions are consistent and evidence-based, although it is important to remember that an algorithm’s fairness and accuracy is only as good as the data it is trained on.
Improving diversity and access
AI can identify wider and more diverse populations by analyzing data across multiple regions and demographics. This reduces the risk of underrepresentation, which helps ensure trial results better reflect real-world patient experiences. Combined with community-based outreach and digital engagement, AI enables more inclusive recruitment strategies.
AI in trial conduct and monitoring
Real-time data analysis
Once a study is underway, AI can process and interpret data as it’s collected. This allows researchers to spot anomalies, detect adverse events, and flag trends that may affect outcomes much sooner than manual monitoring. We know early detection enables faster responses, better patient safety and more reliable results.
Reducing administrative burden
AI can automate time-consuming administrative tasks such as data cleaning, quality checks, and report generation. This frees up site staff and clinical teams to focus on other parts of the clinical trial, including supporting patients and maintaining engagement throughout the study. Automation also reduces the likelihood of human error, improving data integrity.
Challenges and considerations
Data quality and ethics
AI is only as effective as the data it learns from. Incomplete or biased datasets can lead to flawed predictions and potential inequities in patient recruitment and ongoing patient engagement. Sponsors must ensure high standards and complete transparency in how algorithms are trained and maintain robust data governance to comply with evolving regulations across countries and regions.
Accessibility and inclusion
Not all patients have equal access to technology or feel comfortable using digital platforms. Combining AI and other digital technologies with offline human support helps bridge this gap, ensuring patients are never excluded because of technological barriers.
Maintaining oversight
AI can identify insights quickly, but clinical judgment remains essential. Human oversight ensures findings are interpreted correctly and decisions are always made with patients’ well-being as the top priority.
Complementing AI with human support
The human connection
While AI can facilitate efficiencies in time, cost and resource, technology alone can’t replace empathy or personal reassurance. Our Clinical Enrollment Managers (CEMs) (link: /services/site-optimization), for instance, work directly with sites in their local country to create bespoke enrollment strategies and share best practice, which is always well received. Meanwhile, many patients still want a trusted point of contact to answer questions and guide them through their clinical trial journey. We know personalized care, such as listening to patients’ problems, and the relationship participants have with research staff play an important role in retention [3].
The role of our Patient Support Center
Our Patient Support Center (link: /services/navigator) works alongside modern technologies to provide much-needed human support to both patients and sites.
For sites, our Patient Support Center team can take charge of prescreening all digital referrals. In many cases, this reduces the workload of site staff significantly. By managing all communication with potential participants and helping them navigate the prescreening process, this ensures only high-quality referrals progress. This is a crucial advantage as AI-driven recruitment generates larger patient volumes.
Once enrolled, all participants and their caregivers have access to our team of ‘Patient Navigators’. These in-country clinical trial experts provide clear communication and ongoing reassurance and assistance with study-related questions. They also offer a ‘listening ear’ for those times when patients and caregivers just want to talk.
Sponsors, CROs and sites tell us how our Patient Support Center enhances retention rates, boosts screening efficiency, and reduces site burden, making it the perfect complement to technology-driven clinical trial models.
Looking ahead
A hybrid future
The future of clinical trials will blend AI innovation with patient-centered care and engagement. As predictive analytics, automation, and digital platforms continue to evolve, they’ll accelerate drug discovery and streamline clinical trial operations. Yet human connection will remain central to success, ensuring patients, their caregivers and site staff feel informed, supported, valued and empowered throughout the entire process.
When technology and empathy align
When AI’s analytical power meets personalized services like our CEMs and Patient Support Center, trials become more efficient, inclusive, and compassionate. Mastering the balance between innovation and empathetic engagement is the ‘secret sauce’ to accelerate clinical trials in the years ahead.
Ready to explore how AI combined with human support can transform your next study? Get in touch to learn how our Patient Support Center and digital solutions can accelerate your clinical trial.
References
- Brøgger-Mikkelsen, M., Ali, Z., Zibert, J. R., Andersen, A. D., & Thomsen, S. F. (2020). Online Patient Recruitment in Clinical Trials: Systematic Review and Meta-Analysis. Journal of Medical Internet Research, 22(11), e22179. https://doi.org/10.2196/22179
- Mba, K. G. (2025, January 14). How much does a day of delay in a clinical trial really cost? Applied Clinical Trials. https://www.appliedclinicaltrialsonline.com/view/how-much-does-a-day-of-delay-in-a-clinical-trial-really-cost-
- Poongothai, S., Anjana, R. M., Aarthy, R., Unnikrishnan, R., Narayan, K. M. V., Ali, M. K., Karkuzhali, K., & Mohan, V. (2022b). Strategies for participant retention in long term clinical trials. Perspectives in Clinical Research, 14(1), 3–9. https://doi.org/10.4103/picr.picr_161_21